CN110662538A - 甲酰肽受体2/脂氧素a4受体(fpr2/alx)激动剂用于治疗心力衰竭的新用途 - Google Patents
甲酰肽受体2/脂氧素a4受体(fpr2/alx)激动剂用于治疗心力衰竭的新用途 Download PDFInfo
- Publication number
- CN110662538A CN110662538A CN201880033663.XA CN201880033663A CN110662538A CN 110662538 A CN110662538 A CN 110662538A CN 201880033663 A CN201880033663 A CN 201880033663A CN 110662538 A CN110662538 A CN 110662538A
- Authority
- CN
- China
- Prior art keywords
- compound
- heart failure
- treatment
- administration
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762509489P | 2017-05-22 | 2017-05-22 | |
| US62/509,489 | 2017-05-22 | ||
| PCT/US2018/033783 WO2018217684A1 (en) | 2017-05-22 | 2018-05-22 | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110662538A true CN110662538A (zh) | 2020-01-07 |
Family
ID=62567841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880033663.XA Pending CN110662538A (zh) | 2017-05-22 | 2018-05-22 | 甲酰肽受体2/脂氧素a4受体(fpr2/alx)激动剂用于治疗心力衰竭的新用途 |
Country Status (15)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116390913A (zh) * | 2020-10-09 | 2023-07-04 | 百时美施贵宝公司 | 氨基咪唑fpr2激动剂 |
| CN117503932A (zh) * | 2022-07-30 | 2024-02-06 | 中国医学科学院阜外医院 | Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102615095B1 (ko) * | 2017-06-09 | 2023-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 효능제 |
| EP4178946A1 (en) | 2020-07-09 | 2023-05-17 | Bristol-Myers Squibb Company | Oxopyrrolidine fpr2 agonists |
| ES2986512T3 (es) | 2020-07-09 | 2024-11-11 | Bristol Myers Squibb Co | Agonistas del receptor 2 del péptido formil pirazolona |
| WO2022035923A1 (en) | 2020-08-12 | 2022-02-17 | Bristol-Myers Squibb Company | Oxopyrrolidine urea fpr2 agonists |
| CN118831080B (zh) * | 2024-09-24 | 2024-11-22 | 上海交通大学医学院附属仁济医院 | 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150106492A (ko) * | 2014-03-11 | 2015-09-22 | 포항공과대학교 산학협력단 | Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물 |
| CN105814019A (zh) * | 2013-11-28 | 2016-07-27 | 杏林制药株式会社 | 脲衍生物、或其药理学上所容许的盐 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005536187A (ja) * | 2002-04-03 | 2005-12-02 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療 |
-
2018
- 2018-05-22 WO PCT/US2018/033783 patent/WO2018217684A1/en not_active Ceased
- 2018-05-22 MX MX2019013926A patent/MX2019013926A/es unknown
- 2018-05-22 BR BR112019024185-0A patent/BR112019024185A2/pt not_active Application Discontinuation
- 2018-05-22 US US16/612,438 patent/US20200069644A1/en not_active Abandoned
- 2018-05-22 JP JP2019564446A patent/JP2020520948A/ja active Pending
- 2018-05-22 EP EP18730584.2A patent/EP3630097A1/en not_active Withdrawn
- 2018-05-22 EA EA201992704A patent/EA201992704A1/ru unknown
- 2018-05-22 AU AU2018273382A patent/AU2018273382A1/en not_active Abandoned
- 2018-05-22 PE PE2019002437A patent/PE20200402A1/es unknown
- 2018-05-22 KR KR1020197037388A patent/KR20200006595A/ko not_active Withdrawn
- 2018-05-22 CN CN201880033663.XA patent/CN110662538A/zh active Pending
- 2018-05-22 CA CA3064291A patent/CA3064291A1/en active Pending
-
2019
- 2019-11-18 IL IL270749A patent/IL270749A/en unknown
- 2019-11-20 CL CL2019003325A patent/CL2019003325A1/es unknown
- 2019-11-21 CO CONC2019/0013015A patent/CO2019013015A2/es unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105814019A (zh) * | 2013-11-28 | 2016-07-27 | 杏林制药株式会社 | 脲衍生物、或其药理学上所容许的盐 |
| KR20150106492A (ko) * | 2014-03-11 | 2015-09-22 | 포항공과대학교 산학협력단 | Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물 |
Non-Patent Citations (1)
| Title |
|---|
| SOON CHUL HEO等: "Formyl Peptide Receptor 2 Is Involved in Cardiac Repair After Myocardial Infarction Through Mobilization of Circulating Angiogenic Cells", 《STEM CELLS》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116390913A (zh) * | 2020-10-09 | 2023-07-04 | 百时美施贵宝公司 | 氨基咪唑fpr2激动剂 |
| CN117503932A (zh) * | 2022-07-30 | 2024-02-06 | 中国医学科学院阜外医院 | Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018273382A1 (en) | 2020-01-16 |
| IL270749A (en) | 2020-01-30 |
| EP3630097A1 (en) | 2020-04-08 |
| CL2019003325A1 (es) | 2020-04-17 |
| CO2019013015A2 (es) | 2020-01-17 |
| BR112019024185A2 (pt) | 2020-06-02 |
| MX2019013926A (es) | 2020-01-20 |
| WO2018217684A1 (en) | 2018-11-29 |
| KR20200006595A (ko) | 2020-01-20 |
| CA3064291A1 (en) | 2018-11-29 |
| US20200069644A1 (en) | 2020-03-05 |
| PE20200402A1 (es) | 2020-02-26 |
| JP2020520948A (ja) | 2020-07-16 |
| EA201992704A1 (ru) | 2020-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200069644A1 (en) | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure | |
| AU2024200693B2 (en) | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof | |
| Wu et al. | Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats | |
| JP2018016647A (ja) | 新規方法 | |
| JP2020526483A (ja) | 心筋節活性化剤で心不全を治療する方法 | |
| US20080032933A1 (en) | Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides | |
| JP2022523645A (ja) | ミトコンドリアミオパチーの処置におけるPPARδアゴニストの使用 | |
| AU2022299103B2 (en) | Methods of using aldosterone synthase inhibitors | |
| US20180325869A1 (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| US12253531B2 (en) | Diagnostic or predictor of relapsing remitting multiple sclerosis | |
| CN118340787A (zh) | 药物 | |
| US20250152671A1 (en) | Medical composition for treating patients exhibiting cardiac decompensation | |
| TW200848012A (en) | Combination of metformin R-(+)lipoate and antihypertensive agents for the treatment of diabetic hyperglycemia and diabetic complications | |
| JP6688503B2 (ja) | 医薬用組成物 | |
| US20130210861A1 (en) | Methods and compositions for managing cardiovascular disease associated with chronic kidney disease | |
| TW201904584A (zh) | 減少或預防第ii型糖尿病患者中心血管事件之方法 | |
| US12419863B2 (en) | Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy | |
| CN103203009B (zh) | 一种五肽的部分代谢物用于制备抗心肌缺血产品的新用途 | |
| Guidat et al. | Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases | |
| US20230381190A1 (en) | Methods and Treatment for Complex Lymphatic Malformations | |
| WO2023200738A1 (en) | Combination treatment of dilated cardiomyopathy comprising a tyrosine kinase inhibitor and a statin | |
| WO2025245334A1 (en) | Compounds that inhibit the interaction between tristetraprolin and cnot1 and methods of use | |
| WO2023229605A1 (en) | Methods and treatment for complex lymphatic malformations | |
| CN120957749A (zh) | 一种sglt2抑制剂与薄荷醇的组合及其治疗心脏疾病的用途 | |
| EA042615B1 (ru) | Способы лечения синдрома альпорта и улучшения функции почек с использованием бардоксолон-метила |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200107 |
|
| WD01 | Invention patent application deemed withdrawn after publication |